Clinical Trial Update: Study to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet System) 15 mcg [Phase 3]

View source ↗

Summary

Phase 3 clinical trial assessing the Zalviso System (sufentanil sublingual tablet) for moderate-to-severe acute pain has completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Moderate-to-severe Acute Pain
• Pain

Drugs mentioned

• Zalviso System (sufentanil)

Snippet

Sponsor: Talphera, Inc | Conditions: Moderate-to-severe Acute Pain | Phase 3 | Status: COMPLETED | Results posted: 2018-08-08